Immunogenic compositions for the prevention and treatment of meningococcal disease
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/095
A61K-039/02
A61K-039/116
A61K-039/38
A61K-038/00
C07K-014/00
C07K-002/00
출원번호
UP-0652870
(2003-09-02)
등록번호
US-7785608
(2010-09-20)
발명자
/ 주소
Zlotnick, Gary W.
Fletcher, Leah Diane
Farley, John Erwin
Bernfield, Liesel A.
Zagursky, Robert J.
Metcalf, Benjamin J.
출원인 / 주소
Wyeth Holdings Corporation
대리인 / 주소
Sullivan, Kelly M.
인용정보
피인용 횟수 :
46인용 특허 :
31
초록▼
The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and
The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
대표청구항▼
What is claimed is: 1. A composition comprising at least one isolated and purified immunogenic protein comprising any of even numbered SEQ ID NOS: 62-66. 2. The composition of claim 1, wherein the at least one protein has a molecular weight of about 26,000-30,000 daltons as measured by mass spect
What is claimed is: 1. A composition comprising at least one isolated and purified immunogenic protein comprising any of even numbered SEQ ID NOS: 62-66. 2. The composition of claim 1, wherein the at least one protein has a molecular weight of about 26,000-30,000 daltons as measured by mass spectroscopy. 3. The composition of claim 1, wherein the at least one protein has a molecular weight of about 28-35 kDa as measured on a 10%-20% SDS polyacrylamide gel. 4. The composition of claim 1, wherein said composition additionally comprises a pharmaceutically acceptable buffer, diluent, adjuvant or carrier. 5. The composition of claim 1, wherein said composition additionally comprises a carrier. 6. The composition of claim 1, wherein said composition additionally comprises an adjuvant. 7. The composition of claim 6, wherein said adjuvant comprises a liquid. 8. The composition of claim 1, wherein the at least one protein is non-lipidated. 9. The composition of claim 1, wherein the at least one protein is a recombinant protein. 10. The composition of claim 1, wherein the at least one protein is isolated from native Neisseria species. 11. The composition of claim 1, wherein the at least one protein is a lipoprotein. 12. The composition of claim 1, wherein the composition additionally comprises at least one Neisseria meningitidis Por A protein. 13. The composition of claim 1, wherein the composition additionally comprises at least one additional surface antigen of Neisseria species, said additional surface antigen being a non-ORF2086 protein. 14. The composition of claim 1, wherein said composition additionally comprises a polysaccharide. 15. The composition of claim 1 additionally comprising at least one protein comprising the amino acid sequence of any of even numbered SEQ ID NOS: 176-180 or 236-246. 16. The composition of claim 1, wherein the at least one protein comprises the amino acid sequence of any of even numbered SEQ ID NOS: 2-12. 17. The composition of claim 1, wherein the at least one protein comprises the amino acid sequence of any of even numbered SEQ ID NOS: 14-24. 18. The composition of claim 1, wherein the at least one protein comprises the amino acid sequence of any of even numbered SEQ ID NOS: 32-42. 19. The composition of claim 1, wherein the at least one protein comprises the amino acid sequence of any of even numbered SEQ ID NOS: 122-126. 20. The composition of claim 1, wherein the at least one protein comprises the amino acid sequence of any of even numbered SEQ ID NOS: 146-150. 21. The composition of claim 1, wherein the at least one protein comprises the amino acid sequence of any of even numbered SEQ ID NOS: 158-168. 22. The composition of claim 1, wherein the at least one protein comprises the amino acid sequence of any of even numbered SEQ ID NOS: 236-246. 23. A method of inducing an immune response in a mammal comprising administering to the mammal an effective amount of the composition of claim 1. 24. The method of claim 23, wherein said composition is administered parenterally. 25. The method of claim 23, wherein said composition is administered mucosally.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (31)
Muzyczka Nicholas (Stony Brook NY) Hermonat Paul L. (Bethesda MD) Berns Kenneth I. (Mamaroneck NY) Samulski Richard J. (Princeton NJ), AAV transduction vectors.
Conlon ; III Paul J. (Seattle WA) Grabstein Kenneth H. (Seattle WA), Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor.
Felgner Philip L. (Rancho Santa Fe CA) Kumar Raj (San Diego CA) Basava Channa (San Diego CA) Border Richard C. (Poway CA) Hwang-Felgner Jiin-Yu (Rancho Santa Fe CA), Cationic lipids for intracellular delivery of biologically active molecules.
Felgner Philip L. (Rancho Santa Fe CA) Wolff Jon A. (Madison WI) Rhodes Gary H. (Leucadia CA) Malone Robert W. (Chicago IL) Carson Dennis A. (Del Mar CA), Delivery of exogenous DNA sequences in a mammal.
Felgner Philip L. (Rancho Santa Fe CA) Wolff Jon A. (Madison WI) Rhodes Gary H. (Leucadia CA) Malone Robert W. (Chicago IL) Carson Dennis A. (Del Mar CA), Induction of a protective immune response in a mammal by injecting a DNA sequence.
Kuo Joseph S.-C. (Tappan NY) Ree Heesoo K. (Kyongbuk KRX), Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections.
Zlotnick, Gary W.; Fletcher, Leah Diane; Farley, John Erwin; Bernfield, Liesel A.; Zagursky, Robert J.; Metcalf, Benjamin J., Immunogenic compositions for the prevention and treatment of meningococcal disease.
Zlotnick, Gary W.; Fletcher, Leah Diane; Farley, John Erwin; Bernfield, Liesel A.; Zagursky, Robert J.; Metcalf, Benjamin J., Immunogenic compositions for the prevention and treatment of meningococcal disease.
Zlotnick, Gary W.; Fletcher, Leah Diane; Farley, John Erwin; Bernfield, Liesel A.; Zagursky, Robert J.; Metcalf, Benjamin J., Immunogenic compositions for the prevention and treatment of meningococcal disease.
Zlotnick, Gary W.; Fletcher, Leah Diane; Farley, John Erwin; Bernfield, Liesel A.; Zagursky, Robert J.; Metcalf, Benjamin J., Immunogenic compositions for the prevention and treatment of meningococcal disease.
Zlotnick, Gary W.; Fletcher, Leah Diane; Farley, John Erwin; Bernfield, Liesel A.; Zagursky, Robert J.; Metcalf, Benjamin J., Immunogenic compositions for the prevention and treatment of meningococcal disease.
Zlotnick, Gary W.; Fletcher, Leah Diane; Farley, John Erwin; Bernfield, Liesel A.; Zagursky, Robert J.; Metcalf, Benjamin J., Immunogenic compositions for the prevention and treatment of meningococcal disease.
Zlotnick, Gary W.; Fletcher, Leah Diane; Farley, John Erwin; Bernfield, Liesel A.; Zagursky, Robert J.; Metcalf, Benjamin J., Immunogenic compositions for the prevention and treatment of meningococcal disease.
Zlotnick, Gary Warren; Hoiseth, Susan Kay; Jansen, Kathrin Ute; Moran, Justin Keith; Ruppen, Mark E.; Anderson, Annaliesa Sybil; Farley, John Erwin; Bernfield, Liesel A., Neisseria meningitidis compositions and methods thereof.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.